GlassScriptPhysician profile
David R Baldinger
NPI 1144228362
$19,695.51
in general payments reported to CMS, 2019-2025
40 companies · $2,650 in 2025
The $2,650 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,619 · 2020: $1,420 · 2021: $2,042 · 2022: $4,195 · 2023: $4,465 · 2024: $3,305 · 2025: $2,650.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $13.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,406.12 |
| Education | $13.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $4,901.77 | 2019-2025 | Enbrel, Otezla, Tavneos |
| Mallinckrodt Hospital Products INC. | $2,384.32 | 2020-2025 | Acthar |
| Abbvie INC. | $2,147.22 | 2019-2025 | Rinvoq, Skyrizi |
| Ucb, INC. | $1,716.98 | 2019-2025 | Cimzia, Bimzelx, Briviact |
| Janssen Biotech, INC. | $1,406.64 | 2020-2025 | Tremfya, Remicade, Stelara |
| Pfizer INC. | $916.41 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $668.12 | 2019-2025 | Ofev, Cyltezo |
| Lilly USA, LLC | $610.06 | 2019-2024 | Taltz |
| Glaxosmithkline, LLC. | $542.34 | 2021-2025 | Benlysta |
| Radius Health, INC. | $527.23 | 2019-2025 | Tymlos |
| Astrazeneca Pharmaceuticals LP | $526.70 | 2021-2025 | Saphnelo |
| Horizon Therapeutics Plc | $495.81 | 2019-2023 | Krystexxa |
| E.R. Squibb & Sons, L.L.C. | $482.54 | 2019-2025 | Orencia |
| Genzyme Corporation | $445.17 | 2019-2025 | |
| Aurinia Pharma U.S., INC. | $235.81 | 2021-2025 | Lupkynis |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Baldinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.